Objective:
To update on reimbursement, regulatory developments, and advocacy priorities affecting ophthalmic ambulatory surgery centers (ASCs).
Key Findings:
- Successful advocacy resulted in a $150 million increase for ASCs performing cataract surgery.
- CMS will determine the update factor for ASCs in 2027, with a recommendation to retain the Hospital Market Basket.
- OOSS is concerned about narrow definitions for non-opioid drug payments and ongoing payment limitations for MIGS procedures.
Interpretation:
Advocacy efforts have proven effective in influencing reimbursement policies for ASCs, emphasizing the need for continued engagement and vigilance in monitoring regulatory changes.
Limitations:
- Potential future restrictions on payments for vital eyecare services.
- Limited access to hospitals and ASCs for retinal surgical care.
Conclusion:
Active participation in advocacy is crucial for maintaining and improving reimbursement policies for ASCs, with a call to action for members to engage with legislators.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.